Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study.

Published on Mar 23, 2020in Canadian Medical Association Journal6.938
· DOI :10.1503/CMAJ.191012
Teumzghi F. Mebrahtu5
Estimated H-index: 5
Ann W. Morgan44
Estimated H-index: 44
+ 2 AuthorsMar Pujades-Rodriguez26
Estimated H-index: 26
BACKGROUND: Only a few population-based studies have examined the association between glucocorticoids and hypertension, with inconsistent results. We aimed to investigate the effect of oral glucocorticoids on incidence of hypertension in adults with chronic inflammatory diseases. METHODS: We analyzed electronic health records from 389 practices in England during 1998–2017 of adults diagnosed with any of 6 chronic inflammatory diseases but with no previous diagnosis of hypertension. We used glucocorticoid prescription data to construct time-variant daily and cumulative variables of prednisolone-equivalent dose (cumulated from 1 year before the start of follow-up) and estimated incidence rates and adjusted hazard ratios (HRs) for hypertension using Cox regression analysis. RESULTS: Among 71 642 patients in the cohort, 24 896 (34.8%) developed hypertension during a median follow-up of 6.6 years. The incidence rate of hypertension was 46.7 (95% confidence interval [CI] 46.0–47.3) per 1000 person-years. Incidence rates increased with higher cumulative glucocorticoid prednisolone-equivalent dose, from 44.4 per 1000 person-years in periods of nonuse to 45.3 per 1000 person-years for periods with between > 0.0 and 959.9 mg (HR 1.14, 95% CI 1.09–1.19), to 49.3 per 1000 person-years for periods with 960–3054.9 mg (HR 1.20, 95% CI 1.14–1.27), and to 55.6 per 1000 person-years for periods with ≥ 3055 mg (HR 1.30, 95% CI 1.25–1.35). Cumulative effects were seen for the 6 diseases studied, but dose–response effects were not found for daily dose. INTERPRETATION: Cumulative dose of oral glucocorticoids was associated with increased incidence of hypertension, suggesting that blood pressure should be monitored closely in patients routinely treated with these drugs. Given that glucocorticoids are widely prescribed, the associated health burden could be high. Trial registration: ClinicalTrials. gov, no. NCT03760562.
  • References (24)
  • Citations (1)
📖 Papers frequently viewed together
3 Citations
3 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Bernhard Hellmich (University of Tübingen)H-Index: 35
#2Ana Filipa ÁguedaH-Index: 3
Last. Raashid Luqmani (University of Oxford)H-Index: 53
view all 26 authors...
Background Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical trials and cohort analyses have been published, which have the potential to change clinical care and therefore supporting the need to update the original recommendations. Methods Using EULAR standardised operating procedures for EULAR-endorsed recommendations, the EULAR task force undertook a systemati...
7 CitationsSource
#2Christopher A. Lamb (Newcastle University)H-Index: 19
#3Nicholas A. Kennedy (University of Exeter)H-Index: 26
Last. A. Barney Hawthorne (University Hospital of Wales)H-Index: 5
view all 29 authors...
Ulcerative colitis and Crohn’s disease are the principal forms of inflammatory bowel disease. Both represent chronic inflammation of the gastrointestinal tract, which displays heterogeneity in inflammatory and symptomatic burden between patients and within individuals over time. Optimal management relies on understanding and tailoring evidence-based interventions by clinicians in partnership with patients. This guideline for management of inflammatory bowel disease in adults over 16 years of age...
22 CitationsSource
BACKGROUND: Most patients with polymyalgia rheumatica or giant cell arteritis are treated with glucocorticoid therapy in primary care. We estimated dose–response risks of infection for this population in England. METHODS: We conducted a retrospective record-linkage study involving a cohort of people with polymyalgia rheumatica or giant cell arteritis registered in family practices across England (1998–2017). Estimates of first occurring infection per level of time-variant current and cumulative ...
1 CitationsSource
#1Teumzghi F. Mebrahtu (University of Leeds)H-Index: 5
#2Ann W. Morgan (University of Leeds)H-Index: 44
Last. Mar Pujades-Rodriguez (University of Leeds)H-Index: 26
view all 6 authors...
1 CitationsSource
#1Marlene Bloechliger (University of Basel)H-Index: 6
#2Daphne Reinau (University of Basel)H-Index: 7
Last. Christoph R. Meier (University of Basel)H-Index: 49
view all 8 authors...
Background To evaluate the adverse events profile of oral prednisolone among adult asthma patients in the UK.
10 CitationsSource
#1Caroline Gordon (University of Birmingham)H-Index: 72
#2Maame-Boatemaa Amissah-Arthur (University of Birmingham)H-Index: 3
Last. David A. Isenberg (UCL: University College London)H-Index: 103
view all 15 authors...
46 CitationsSource
#1J. Bradford Rice (AG: Analysis Group)H-Index: 11
#2Alan G. White (AG: Analysis Group)H-Index: 14
Last. Winnie W. NelsonH-Index: 19
view all 5 authors...
Abstract Purpose While corticosteroids are relatively inexpensive and commonly used as treatment for a variety of conditions, long-term use is known to be associated with certain toxicities. Prior systematic reviews have revealed an increased risk for costly adverse events (AEs), including bone fracture, infection, and gastrointestinal bleeding. The objective of this study was to conduct a systematic literature review of recent publications on the burden of long-term corticosteroid exposure, spe...
20 CitationsSource
#1Mohammad Movahedi (University of Manchester)H-Index: 5
#2Ruth Costello (University of Manchester)H-Index: 4
Last. William G. Dixon (University of Manchester)H-Index: 35
view all 6 authors...
Previous studies of glucocorticoid (GC) therapy and mortality have had inconsistent results and have not considered possible perimortal bias—a type of protopathic bias where illness in the latter stages of life influences GC exposure, and might affect the observed relationship between GC use and death. This study aimed to investigate all-cause and cause-specific mortality in association with GC therapy in patients with rheumatoid arthritis (RA), and explore possible perimortal bias. A retrospect...
18 CitationsSource
#1Rosario PivonelloH-Index: 63
#2Aldo Isidori (Sapienza University of Rome)H-Index: 44
Last. Annamaria ColaoH-Index: 83
view all 6 authors...
Summary Cushing's syndrome is a serious endocrine disease caused by chronic, autonomous, and excessive secretion of cortisol. The syndrome is associated with increased mortality and impaired quality of life because of the occurrence of comorbidities. These clinical complications include metabolic syndrome, consisting of systemic arterial hypertension, visceral obesity, impairment of glucose metabolism, and dyslipidaemia; musculoskeletal disorders, such as myopathy, osteoporosis, and skeletal fra...
69 CitationsSource
#1Meng-Sui Lee (NYMU: National Yang-Ming University)H-Index: 3
#2Chia-Hsuin Chang (NTU: National Taiwan University)H-Index: 31
Last. Mei-Shu Lai (NTU: National Taiwan University)H-Index: 37
view all 4 authors...
Purpose Patients with psoriasis and/or psoriatic arthritis (PsA) are known to have increased cardiovascular morbidity and mortality. Hypertension, an important risk factor for cardiovascular disease, is highly prevalent in patients with psoriasis and/or PsA. The effects of anti-psoriatic medications – including cyclosporine, nonsteroidal anti-inflammatory drugs, and glucocorticoids – on hypertension remain unclear. We examined whether such medication exposure was associated with hypertension in ...
10 CitationsSource
Cited By1